These studies on the regulation network of EGFR-miRNAs highlight the possibility that in addition to tyrosine kinase inhibitors and classical monoclonal antibodies for EGFR-targeted therapies, miRNA-based therapy could be utilized to target EGFR.31 Moreover, study has shown that the therapeutic potential of miR-34a delivery in combination with radiotherapy may represent a novel strategy for treating NSCLC.30 Meanwhile, there are many verified and predicted targets of miR-34a (Supplementary Table S4). This evidence concerns the gene EGFR and non-small cell lung carcinoma.